Several PPAR-modulating agents, with varying degrees of affinity for the different PPAR isotypes, have been investigated for the therapy of NAFLD and NASH (Figure 2). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.